# Maravai Lifesciences Holdings, Inc.: financial statements, quarterly

MRVI · Nasdaq · CIK 1823239 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrvi.md) · [Financials](/companies/mrvi/financials.md) · [Filings](/companies/mrvi/filings.md) · [Insiders](/companies/mrvi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mrvi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [66.9](/filings/0001823239-24-000118.md) | [74.1 d](/filings/0001823239-26-000011.md) | [64.2](/filings/0001823239-25-000063.md) | [69.4](/filings/0001823239-25-000107.md) | [69.0](/filings/0001823239-25-000120.md) | [56.6 d](/filings/0001823239-26-000011.md) | [46.9](/filings/0001823239-26-000024.md) | [47.4](/filings/0001823239-26-000059.md) | [41.6](/filings/0001823239-25-000120.md) | [49.9 d](/filings/0001823239-26-000011.md) | [65.8](/filings/0001823239-26-000024.md) | [51.4](/filings/0001823239-26-000059.md) |
| Cost of revenue | $m | [36.7](/filings/0001823239-24-000118.md) | [35.1 d](/filings/0001823239-26-000011.md) | [38.3](/filings/0001823239-25-000063.md) | [38.6](/filings/0001823239-25-000107.md) | [36.8](/filings/0001823239-25-000120.md) | [37.2 d](/filings/0001823239-26-000011.md) | [39.1](/filings/0001823239-26-000024.md) | [39.6](/filings/0001823239-26-000059.md) | [36.0](/filings/0001823239-25-000120.md) | [37.0 d](/filings/0001823239-26-000011.md) | [32.1](/filings/0001823239-26-000024.md) | [30.8](/filings/0001823239-26-000059.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | [32.2](/filings/0001823239-25-000120.md) | [19.4 d](/filings/0001823239-26-000011.md) | [7.7](/filings/0001823239-26-000024.md) | [7.8](/filings/0001823239-26-000059.md) | [5.7](/filings/0001823239-25-000120.md) | [12.8 d](/filings/0001823239-26-000011.md) | [33.7](/filings/0001823239-26-000024.md) | [20.7](/filings/0001823239-26-000059.md) |
| Research and development | $m | [4.3](/filings/0001823239-24-000118.md) | [4.6 d](/filings/0001823239-26-000011.md) | [5.0](/filings/0001823239-25-000063.md) | [4.9](/filings/0001823239-25-000107.md) | [4.7](/filings/0001823239-25-000120.md) | [4.6 d](/filings/0001823239-26-000011.md) | [4.9](/filings/0001823239-26-000024.md) | [4.9](/filings/0001823239-26-000059.md) | [3.8](/filings/0001823239-25-000120.md) | [3.8 d](/filings/0001823239-26-000011.md) | [3.9](/filings/0001823239-26-000024.md) | [3.7](/filings/0001823239-26-000059.md) |
| Selling, general and administrative | $m | [38.9](/filings/0001823239-24-000118.md) | [38.5 d](/filings/0001823239-26-000011.md) | [40.9](/filings/0001823239-25-000063.md) | [40.6](/filings/0001823239-25-000107.md) | [39.1](/filings/0001823239-25-000120.md) | [41.2 d](/filings/0001823239-26-000011.md) | [39.6](/filings/0001823239-26-000024.md) | [38.7](/filings/0001823239-26-000059.md) | [35.4](/filings/0001823239-25-000120.md) | [31.6 d](/filings/0001823239-26-000011.md) | [29.1](/filings/0001823239-26-000024.md) | [32.1](/filings/0001823239-26-000059.md) |
| Operating income | $m | [(15.4)](/filings/0001823239-24-000118.md) | [(7.2) d](/filings/0001823239-26-000011.md) | [(18.9)](/filings/0001823239-25-000063.md) | [(13.4)](/filings/0001823239-25-000107.md) | [(166)](/filings/0001823239-25-000120.md) | [(37.7) d](/filings/0001823239-26-000011.md) | [(49.2)](/filings/0001823239-26-000024.md) | [(66.3)](/filings/0001823239-26-000059.md) | [(41.0)](/filings/0001823239-25-000120.md) | [(58.8) d](/filings/0001823239-26-000011.md) | [(2.2)](/filings/0001823239-26-000024.md) | [(15.1)](/filings/0001823239-26-000059.md) |
| Interest expense | $m | [11.6](/filings/0001823239-24-000118.md) | [15.4 d](/filings/0001823239-24-000032.md) | [10.9](/filings/0001823239-24-000060.md) | [11.9](/filings/0001823239-24-000095.md) | [13.6](/filings/0001823239-24-000118.md) | [11.3 d](/filings/0001823239-26-000011.md) | [6.8](/filings/0001823239-26-000024.md) | [6.8](/filings/0001823239-26-000059.md) | [6.8](/filings/0001823239-25-000120.md) | [6.6 d](/filings/0001823239-26-000011.md) | [5.7](/filings/0001823239-26-000024.md) | [4.8](/filings/0001823239-26-000059.md) |
| Income tax | $m | [(5.5)](/filings/0001823239-24-000118.md) | [766 d](/filings/0001823239-26-000011.md) | [0.3](/filings/0001823239-25-000063.md) | [(2.4)](/filings/0001823239-25-000107.md) | [0.3](/filings/0001823239-25-000120.md) | [(0.0) d](/filings/0001823239-26-000011.md) | [0.2](/filings/0001823239-26-000024.md) | [(4.3)](/filings/0001823239-26-000059.md) | [(0.1)](/filings/0001823239-25-000120.md) | [0.0 d](/filings/0001823239-26-000011.md) | [(0.2)](/filings/0001823239-26-000024.md) | [(0.2)](/filings/0001823239-26-000059.md) |
| Net income | $m | [(6.5)](/filings/0001823239-24-000118.md) | [(106) d](/filings/0001823239-26-000011.md) | [(12.1)](/filings/0001823239-25-000063.md) | [(9.8)](/filings/0001823239-25-000107.md) | [(97.1)](/filings/0001823239-25-000120.md) | [(25.9) d](/filings/0001823239-26-000011.md) | [(29.9)](/filings/0001823239-26-000024.md) | [(39.6)](/filings/0001823239-26-000059.md) | [(25.6)](/filings/0001823239-25-000120.md) | [(35.7) d](/filings/0001823239-26-000011.md) | [(3.7)](/filings/0001823239-26-000024.md) | [(12.4)](/filings/0001823239-26-000059.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001823239-24-000118.md) | not reported | [(0.09)](/filings/0001823239-25-000063.md) | [(0.07)](/filings/0001823239-25-000107.md) | [(0.68)](/filings/0001823239-25-000120.md) | not reported | [(0.21)](/filings/0001823239-26-000024.md) | [(0.27)](/filings/0001823239-26-000059.md) | [(0.18)](/filings/0001823239-25-000120.md) | not reported | [(0.02)](/filings/0001823239-26-000024.md) | [(0.08)](/filings/0001823239-26-000059.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0001823239-24-000118.md) | not reported | [(0.09)](/filings/0001823239-25-000063.md) | [(0.07)](/filings/0001823239-25-000107.md) | [(0.68)](/filings/0001823239-25-000120.md) | not reported | [(0.21)](/filings/0001823239-26-000024.md) | [(0.27)](/filings/0001823239-26-000059.md) | [(0.18)](/filings/0001823239-25-000120.md) | not reported | [(0.02)](/filings/0001823239-26-000024.md) | [(0.08)](/filings/0001823239-26-000059.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [580](/filings/0001823239-23-000089.md) | [575](/filings/0001823239-25-000034.md) | [562](/filings/0001823239-24-000060.md) | [573](/filings/0001823239-25-000034.md) | [578](/filings/0001823239-25-000034.md) | [322](/filings/0001823239-26-000011.md) | [285](/filings/0001823239-25-000063.md) | [270](/filings/0001823239-26-000059.md) | [244](/filings/0001823239-25-000120.md) | [217](/filings/0001823239-26-000059.md) | [166](/filings/0001823239-26-000024.md) | [70.1](/filings/0001823239-26-000059.md) |
| Current assets | $m | [701](/filings/0001823239-23-000089.md) | [700](/filings/0001823239-25-000034.md) | [668](/filings/0001823239-24-000060.md) | [682](/filings/0001823239-25-000034.md) | [679](/filings/0001823239-25-000034.md) | [429](/filings/0001823239-26-000011.md) | [376](/filings/0001823239-25-000063.md) | [360](/filings/0001823239-25-000107.md) | [326](/filings/0001823239-25-000120.md) | [296](/filings/0001823239-26-000059.md) | [252](/filings/0001823239-26-000024.md) | [156](/filings/0001823239-26-000059.md) |
| Total assets | $m | [2,268](/filings/0001823239-23-000089.md) | [1,487](/filings/0001823239-25-000034.md) | [1,445](/filings/0001823239-24-000060.md) | [1,444](/filings/0001823239-25-000034.md) | [1,278](/filings/0001823239-25-000034.md) | [1,008](/filings/0001823239-26-000011.md) | [960](/filings/0001823239-25-000063.md) | [897](/filings/0001823239-25-000107.md) | [849](/filings/0001823239-25-000120.md) | [771](/filings/0001823239-26-000059.md) | [713](/filings/0001823239-26-000024.md) | [604](/filings/0001823239-26-000059.md) |
| Current liabilities | $m | [78.3](/filings/0001823239-23-000089.md) | [87.5](/filings/0001823239-25-000034.md) | [59.0](/filings/0001823239-24-000060.md) | [68.6](/filings/0001823239-25-000034.md) | [63.7](/filings/0001823239-25-000034.md) | [57.0](/filings/0001823239-26-000011.md) | [63.2](/filings/0001823239-25-000063.md) | [69.7](/filings/0001823239-25-000107.md) | [61.6](/filings/0001823239-25-000120.md) | [44.9](/filings/0001823239-26-000059.md) | [42.6](/filings/0001823239-26-000024.md) | [38.4](/filings/0001823239-26-000059.md) |
| Total liabilities | $m | [1,375](/filings/0001823239-23-000089.md) | [698](/filings/0001823239-25-000034.md) | [667](/filings/0001823239-24-000060.md) | [671](/filings/0001823239-25-000034.md) | [666](/filings/0001823239-25-000034.md) | [431](/filings/0001823239-26-000011.md) | [429](/filings/0001823239-25-000063.md) | [429](/filings/0001823239-25-000107.md) | [417](/filings/0001823239-25-000120.md) | [398](/filings/0001823239-26-000059.md) | [344](/filings/0001823239-26-000024.md) | [248](/filings/0001823239-26-000059.md) |
| Long-term debt | $m | [520](/filings/0001823239-23-000089.md) | [519](/filings/0001823239-25-000034.md) | [518](/filings/0001823239-24-000060.md) | [517](/filings/0001823239-25-000034.md) | [516](/filings/0001823239-25-000034.md) | [290](/filings/0001823239-26-000011.md) | [289](/filings/0001823239-25-000063.md) | [288](/filings/0001823239-25-000107.md) | [287](/filings/0001823239-25-000120.md) | [286](/filings/0001823239-26-000059.md) | [236](/filings/0001823239-26-000024.md) | [146](/filings/0001823239-26-000059.md) |
| Current portion of debt | $m | [5.4](/filings/0001823239-23-000089.md) | [5.4](/filings/0001823239-25-000034.md) | [5.4](/filings/0001823239-24-000060.md) | [5.4](/filings/0001823239-25-000034.md) | [5.4](/filings/0001823239-25-000034.md) | [5.4](/filings/0001823239-26-000011.md) | [5.4](/filings/0001823239-25-000063.md) | [5.4](/filings/0001823239-25-000107.md) | [5.4](/filings/0001823239-25-000120.md) | [5.4](/filings/0001823239-26-000059.md) | [5.4](/filings/0001823239-26-000024.md) | [1.1](/filings/0001823239-26-000059.md) |
| Shareholders' equity | $m | [519](/filings/0001823239-23-000089.md) | [417](/filings/0001823239-25-000034.md) | [411](/filings/0001823239-24-000060.md) | [435](/filings/0001823239-25-000034.md) | [345](/filings/0001823239-25-000034.md) | [325](/filings/0001823239-26-000011.md) | [301](/filings/0001823239-25-000063.md) | [266](/filings/0001823239-25-000107.md) | [245](/filings/0001823239-25-000120.md) | [212](/filings/0001823239-26-000059.md) | [212](/filings/0001823239-26-000024.md) | [205](/filings/0001823239-26-000059.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [14.2 d](/filings/0001823239-24-000118.md) | [7.8 d](/filings/0001823239-26-000011.md) | [(8.5)](/filings/0001823239-25-000063.md) | [17.4 d](/filings/0001823239-25-000107.md) | [13.1 d](/filings/0001823239-25-000120.md) | [(14.6) d](/filings/0001823239-26-000011.md) | [(9.4)](/filings/0001823239-26-000024.md) | [(10.3) d](/filings/0001823239-26-000059.md) | [(15.2) d](/filings/0001823239-25-000120.md) | [(22.8) d](/filings/0001823239-26-000011.md) | [8.7](/filings/0001823239-26-000024.md) | [4.0 d](/filings/0001823239-26-000059.md) |
| Capital expenditure | $m | [15.8 d](/filings/0001823239-24-000118.md) | [16.8 d](/filings/0001823239-26-000011.md) | [5.7](/filings/0001823239-25-000063.md) | [9.6 d](/filings/0001823239-25-000107.md) | [8.6 d](/filings/0001823239-25-000120.md) | [5.8 d](/filings/0001823239-26-000011.md) | [4.5](/filings/0001823239-26-000024.md) | [2.9 d](/filings/0001823239-26-000059.md) | [3.7 d](/filings/0001823239-25-000120.md) | [2.1 d](/filings/0001823239-26-000011.md) | [4.4](/filings/0001823239-26-000024.md) | [0.4 d](/filings/0001823239-26-000059.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [132](/filings/0001823239-23-000089.md) | [132](/filings/0001823239-24-000060.md) | [132](/filings/0001823239-24-000095.md) | [132](/filings/0001823239-24-000118.md) | [132](/filings/0001823239-25-000063.md) | [136](/filings/0001823239-25-000107.md) | [142](/filings/0001823239-25-000120.md) | [143](/filings/0001823239-26-000024.md) | [144](/filings/0001823239-26-000059.md) | [145](/filings/0001823239-25-000120.md) | [146](/filings/0001823239-26-000024.md) | [148](/filings/0001823239-26-000059.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.